Drug Trial Radar · NCT07222969
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Jan 12, 2026
Primary completion
Sep 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Vibrant Sciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments. This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability, PK profile, preliminary antitumor activity and immunogenicity of VIB305 in advanced solid tumors, to determine the nature and incidence of dose-limiting toxicities (DLTs), and thereby to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Based on the findings from the Phase I portion for evaluation in the Phase II portion. Phase II (dose expansion) will enroll additional cohorts to further assess the safety and tolerability, PK profile, preliminary antitumor activity and immunogenicity of VIB305 in specific tumor types (selected based on all available data).
Conditions
- Advanced Solid Tumors
Interventions
VIB305 for InjectionDrug
Intravenous infusion: once every week/every two weeks/every three weeks, each treatment cycle is 3 weeks/4 weeks/6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-related adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and DLTsTime frame: From the first drug administration to 150 days after the last drug administration
- MTD and/or RP2D based on the incidence and nature of DLTsTime frame: From the first drug administration to the last day of DLT observation period
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Sunshine Coast University Private Hospital
Sunshine Coast, Queensland, Australia · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Zhongshan Hospital Affiliated to Dalian University
Dalian, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.